Glucagon-like Peptide 1-Based Drugs and Pancreatic Safety

被引：1
作者：
Brodovicz, Kimberly G. [1 ]
Engel, Samuel S. [1 ]
Thornberry, Nancy A. [1 ]
机构：
[1] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA
来源：
JAMA INTERNAL MEDICINE | 2013年 / 173卷 / 19期
关键词：
SITAGLIPTIN;
D O I：
10.1001/jamainternmed.2013.8138
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1842 / +
页数：2
相关论文
共 50 条
  • [31] Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue
    Retterstol, Kjetil
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (09) : 1405 - 1411
  • [32] Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study
    Tang, Huilin
    Lu, Ying
    Okun, Michael S.
    Donahoo, William T.
    Ramirez-Zamora, Adolfo
    Wang, Fei
    Huang, Yu
    Armstrong, Melissa
    Svensson, Mikael
    Virnig, Beth A.
    DeKosky, Steven T.
    Bian, Jiang
    Guo, Jingchuan
    [J]. MOVEMENT DISORDERS, 2024, 39 (11) : 1960 - 1970
  • [33] Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus
    Camafort-Babkowski, Miguel
    [J]. MEDICINA CLINICA, 2013, 141 (04): : 167 - 174
  • [34] Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
    Song, Xiaoyan
    Jia, Hetang
    Jiang, Yuebo
    Wang, Liang
    Zhang, Yan
    Mu, Yiming
    Liu, Yu
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [35] Glucagon-like peptide-1 and interleukin-6 interaction in response to physical exercise: An in-silico model in the framework of immunometabolism
    Morettini, Micaela
    Palumbo, Maria Concetta
    Bottiglione, Alessandro
    Danieli, Andrea
    Del Giudice, Simone
    Burattini, Laura
    Tura, Andrea
    [J]. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2024, 245
  • [36] Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
    Patel, Kershaw, V
    Sarraju, Ashish
    Neeland, Ian J.
    McGuire, Darren K.
    [J]. CURRENT CARDIOLOGY REPORTS, 2020, 22 (10)
  • [37] Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome
    Bouzas, Cristina
    Pastor, Rosario
    Garcia, Silvia
    Monserrat-Mesquida, Margalida
    Martinez-Gonzalez., Miguel Angel
    Salas-Salvado, Jordi
    Corella, Dolores
    Goday, Albert
    Martinez, J. Alfredo
    Alonso-Gomez, Angel M.
    Fernandez-Barcelo, Olga
    Vioque, Jesus
    Romaguera, Dora
    Lopez-Miranda, Jose
    Estruch, Ramon
    Tinahones, Francisco J.
    Lapetra, Jose
    Serra-Majema, Lluis
    Riquelme-Gallegop, Blanca
    Martin-Sanchez, Vicente
    Pinto, Xavier
    Delgado-Rodriguez, Miguel
    Matia, Pilar
    Vidal, Josep
    Cardenas-Salas, Jersy-Jair
    Daimiel, Lidia
    Ros, Emilio
    Toledo, Estefania
    Manzanares, Josep M.
    Gonzalez-Monge, Inmaculada
    Munoz, Miguel-Angel
    Martinez-Urbistondo, Diego
    Tojal-Sierra, Lucas
    Munoz-Bravoaf, Carlos
    Miralles-Gisbert, Salvador
    Martin, Marian
    Garcia-Rios, Antonio
    Castro-Barquero, Sara
    Fernandez-Garcia, Jose Carlos
    Santos-Lozano, Jose Manuel
    Basterra-Gortari, F. Javier
    Gutierrez-Carrasquilla, Liliana
    Guillem-Saiz, Patricia
    Satorres, Alba
    Abete, Itziar
    Sorto-Sanchez, Carolina
    Diez-Espino, Javier
    Babio, Nancy
    Fito, Montse
    Tur, Josep A.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2023, 161
  • [38] Lack of preservation of insulin gene expression by a Glucagon-Like Peptide 1 agonist or a Dipeptidyl Peptidase 4 inhibitor in an in vivo model of glucolipotoxicity
    Fontes, Ghislaine
    Hagman, Derek K.
    Latour, Martin G.
    Semache, Meriem
    Poitout, Vincent
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 87 (03) : 322 - 328
  • [39] Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes
    Scheen, Andre J.
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2012, 23 (02) : 126 - 131
  • [40] Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?
    Andersen, Emilie S.
    Lund, Asger
    Bagger, Jonatan I.
    Andreasen, Camilla
    Grondahl, Magnus F.
    Deacon, Carolyn F.
    Hartmann, Bolette
    Holst, Jens J.
    Knop, Filip K.
    Vilsboll, Tina
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (08) : 1937 - 1943
12345